Unpacking FDA’s Response to the Alpha-Synuclein Seed Amplification Assay: What Does This Mean for the Future of Parkinson’s Clinical Trials?
Time: 12:00 pm
day: Conference Day Two - Track Three
Details:
- Showcasing the latest advancements of αSyn-SAA in monitoring drug-induced improvement in PD progression
- Highlighting opportunities unlocked by αSyn-SAA to establish objective endpoints and monitor efficacy of PD drugs
